Rob is a Founder and Managing Director at Beacon Prince Partners, a biotechnology and life sciences consulting firm. Previously, he was the Global Head of Strategy for the Immunology and Oncology franchises at Sanofi. ​ 

Rob has worked as CEO of NKT Therapeutics and Alinea Pharmaceuticals, two venture capital backed life sciences firms. He was a partner at Boston Millennia Partners, a private equity firm, where he was on the Board of Directors of Glycofi, Cardiomems, and Sapphire Therapeutics. He served as a Program Executive at Vertex Pharmaceuticals, where he was on the Joint Steering Committee for the Vertex-Novartis kinase collaboration. ​ 

He was also a consultant at McKinsey and Company. Prior to McKinsey, Rob was a board-certified medical oncologist, receiving his training in internal medicine at the University of California, San Francisco, and his training in oncology at the Dana-Farber Cancer Institute. ​ 

Rob received his B.A. and M.D. degrees from Johns Hopkins University.​